IMYX-3
/ Immunyx Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 22, 2026
Modulating immune toxicity in ulcerative colitis using a small molecule RAB27A inhibitor.
(PubMed, Inflamm Bowel Dis)
- "IMYX-3 effectively inhibits RAB27A activation in neutrophils, yielding improved outcomes in preclinical disease models with no major safety concerns."
Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL10 • RAB27A
1 to 1
Of
1
Go to page
1